Characterization of highly stable liposomal and immunoliposomal formulations of vincristine and vinblastine

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 4, 2009, Pages 741-751

  Noble, Charles O ^a   Guo, Zexiong ^a,b   Hayes, Mark E ^a   Marks, James D ^c   Park, John W ^c   Benz, Christopher C ^c,d   Kirpotin, Dmitri B ^a   Drummond, Daryl C ^a  

^a Hermes Biosciences Inc   (United States)

^b THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

Drug delivery; Liposomes; Nanocarrier; Vinca alkaloid; Vincristine

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 2 ANTIBODY; IMMUNOLIPOSOME; LIPOSOME; TRIETHYLAMMONIUM SUCROSEOCTASULFATE; UNCLASSIFIED DRUG; VINBLASTINE SULFATE; VINCRISTINE SULFATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; LIPOSOMES; MICE; RATS; RATS, SPRAGUE-DAWLEY; TRANSPLANTATION, HETEROLOGOUS; VINBLASTINE; VINCRISTINE;

EID: 68149159236     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0923-3     Document Type: Article

References (52)

1. SA Abraham K Edwards G Karlsson S MacIntosh LD Mayer C McKenzie MB Bally 2002 Formation of transition metal-doxorubicin complexes inside liposomes Biochim Biophys Acta 1565 41 54
2. TM Allen WW Cheng JI Hare KM Laginha 2006 Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer Anticancer Agents Med Chem 6 513 523
3. GR Bartlett 1959 Phosphorous assay in column chromatography J Biol Chem 234 466 468
4. AY Bedikian A Vardeleon T Smith S Campbell R Namdari 2006 Pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients J Clin Pharmacol 46 727 737
5. L Boehlke JN Winter 2006 Sphingomyelin/cholesterol liposomal vincristine: a new formulation for an old drug Expert Opin Biol Ther 6 409 415
6. S Cheng WK Evans D Stys-Norman FA Shepherd 2007 Chemotherapy for relapsed small cell lung cancer: a systematic review and practice guideline J Thorac Oncol 2 348 354
7. PR Cullis MJ Hope MB Bally TD Madden LD Mayer DB Fenske 1997 Influence of pH gradients on the transbilayer transport of drugs, lipids, peptides and metal ions into large unilamellar vesicles Biochim Biophys Acta 1331 187 211
8. DC Drummond C Marx Z Guo G Scott C Noble D Wang M Pallavicini DB Kirpotin CC Benz 2005 Enhanced pharmacodynamic and antitumor properties of a histone deacetylase inhibitor encapsulated in liposomes or ErbB2-targeted immunoliposomes Clin Cancer Res 11 3392 3401
9. DC Drummond OM Meyer K Hong DB Kirpotin D Papahadjopoulos 1999 Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors Pharmacol Rev 51 691 743
10. DC Drummond CO Noble ME Hayes JW Park DB Kirpotin 2008 Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development J Pharm Sci 97 4696 4740
11. DC Drummond CO Noble Z Guo K Hong JW Park DB Kirpotin 2006 Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy Cancer Res 66 3271 3277
12. DC Drummond CO Noble ME Hayes JW Park DB Kirpotin 2008 Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development J Pharm Sci 97 4696 4740
13. A Gabizon M Chemla D Tzemach AT Horowitz D Goren 1996 Liposome longevity and stability in circulation: effects on the in vivo delivery to tumors and therapeutic efficacy of encapsulated anthracyclines J Drug Target 3 391 398
14. KA Gelmon A Tolcher AR Diab MB Bally L Embree N Hudon C Dedhar D Ayers A Eisen B Melosky C Burge P Logan LD Mayer 1999 Phase I study of liposomal vincristine J Clin Oncol 17 697 705
15. G Haran R Cohen LK Bar Y Barenholz 1993 Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphiphathic weak bases Biochim Biophys Acta 1151 201 215
16. SK Hobbs WL Monsky F Yuan WG Roberts L Griffith VP Torchilin RK Jain 1998 Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment Proc Natl Acad Sci USA 95 4607 4612
17. JK Horton PJ Houghton JA Houghton 1988 Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts Biochem Pharmacol 37 3995 4000
18. DV Jackson Jr RA Bender 1979 Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro Cancer Res 39 4346 4349
19. MJ Johnston SC Semple SK Klimuk S Ansell N Maurer PR Cullis 2007 Characterization of the drug retention and pharmacokinetic properties of liposomal nanoparticles containing dihydrosphingomyelin Biochim Biophys Acta 1768 1121 1127
20. MJ Johnston SC Semple SK Klimuk K Edwards ML Eisenhardt EC Leng G Karlsson D Yanko PR Cullis 2006 Therapeutically optimized rates of drug release can be achieved by varying the drug-to-lipid ratio in liposomal vincristine formulations Biochim Biophys Acta 1758 55 64
21. DB Kirpotin DC Drummond Y Shao MR Shalaby K Hong UB Nielsen JD Marks CC Benz JW Park 2006 Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models Cancer Res 66 6732 6740
22. DD Lasic PM Frederick MCA Stuart Y Barenholz TJ McIntosh 1992 Gelation of liposome interior: a novel method for drug encapsulation FEBS Lett 312 255 258
23. P Laverman AH Brouwers ETM Dams WJG Oyen G Storm N Van Rooigen FHM Corstens OC Boerman 2000 Preclinical and clincal evidence for disappearance of long-circulating characteristics of polyethylene glycol liposomes at low lipid dose J Pharmacol Exp Ther 293 996 1001
24. SS Legha 1997 Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy Semin Oncol 24 S39 S43
25. MB Lens TG Eisen 2003 Systemic chemotherapy in the treatment of malignant melanoma Expert Opin Pharmacother 4 2205 2211
26. S Lobert J Fahy BT Hill A Duflos C Etievant JJ Correia 2000 Vinca alkaloid-induced tubulin spiral formation correlates with cytotoxicity in the leukemic L1210 cell line Biochemistry 39 12053 12062
27. O Lyass B Uziely R Ben-Yosef D Tzemach NI Heshing M Lotem G Brufman A Gabizon 2000 Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil) in metastatic breast carcinoma Cancer 89 1037 1047
28. H Maeda Y Matsumura 1989 Tumoritropic and lymphotropic principles of macromolecular drugs CRC Crit Rev Therap Drug Carrier System 6 193 210
29. C Mamot DC Drummond CO Noble V Kallab Z Guo K Hong DB Kirpotin JW Park 2005 Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo Cancer Res 65 11631 11638
30. LD Mayer MB Bally MJ Hope PR Cullis 1985 Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential Biochim Biophys Acta 816 294 302
31. LD Mayer MB Bally H Loughrey D Masin PR Cullis 1990 Liposomal vincristine preparations which exhibit decreased drug toxicity and increased activity against murine L1210 and P388 tumors Cancer Res 50 575 579
32. LD Mayer R Nayar RL Thies NL Boman PR Cullis MB Bally 1993 Identification of vesicle properties that enhance the antitumor activity of liposomal vincristine against murine L1210 leukemia Cancer Chemother Pharmacol 33 17 24
33. DF Nellis DL Ekstrom DB Kirpotin J Zhu R Andersson TL Broadt TF Ouellette SC Perkins JM Roach DC Drummond K Hong JD Marks JW Park SL Giardina 2005 Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification Biotechnol Prog 21 205 220 (Pubitemid 40218491)
34. DF Nellis SL Giardina GM Janini SR Shenoy JD Marks R Tsai DC Drummond K Hong JW Park TF Ouellette SC Perkins DB Kirpotin 2005 Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis Biotechnol Prog 21 221 232
35. UB Nielsen DB Kirpotin EM Pickering K Hong JW Park M Refaat Shalaby Y Shao CC Benz JD Marks 2002 Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis Biochim Biophys Acta 1591 109 118
36. CO Noble DB Kirpotin ME Hayes C Mamot K Hong JW Park CC Benz JD Marks DC Drummond 2004 Development of ligand-targeted liposomes for cancer therapy Expert Opin Ther Targets 8 335 353
37. JW Park K Hong DB Kirpotin G Colbern R Shalaby J Baselga Y Shao UB Nielsen JD Marks D Moore D Papahadjopoulos CC Benz 2002 Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery Clin Cancer Res 8 1172 1181
38. AD Pearson CR Pinkerton IJ Lewis J Imeson C Ellershaw D Machin 2008 High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial Lancet Oncol 9 247 256
39. CR Pinkerton MP Blanc Vincent C Bergeron B Fervers T Philip 2000 Induction chemotherapy in metastatic neuroblastoma-does dose influence response? A critical review of published data standards, options and recommendations (SOR) project of the National Federation of French Cancer Centres (FNCLCC) Eur J Cancer 36 1808 1815
40. MA Poul B Becerril UB Nielsen P Morisson JD Marks 2000 Selection of tumor-specific internalizing human antibodies from phage libraries J Mol Biol 301 1149 1161
41. Rowinsky E, Donehower R (1996) Antimicrotubule Agents. In: Chabner B, Longo D (eds) Cancer chemotherapy and biotherapy: principles and practice. Lippincott-Raven Publishers, Philadelphia, pp 263-296
42. P Sapra TM Allen 2003 Ligand-targeted liposomal anticancer drugs Prog Lipid Res 42 439 462
43. P Sapra TM Allen 2004 Improved outcome when B-cell lymphoma is treated with combinations of immunoliposomal anticancer drugs targeted to both the CD19 and CD20 epitopes Clin Cancer Res 10 2530 2537
44. P Sapra EH Moase J Ma TM Allen 2004 Improved therapeutic responses in a xenograft model of human B lymphoma (Namalwa) for liposomal vincristine versus liposomal doxorubicin targeted via anti-CD19 IgG2a or Fab' fragments Clin Cancer Res 10 1100 1111
45. SC Semple R Leone J Wang EC Leng SK Klimuk ML Eisenhardt ZN Yuan K Edwards N Maurer MJ Hope PR Cullis QF Ahkong 2005 Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity J Pharm Sci 94 1024 1038
46. DA Thomas AH Sarris J Cortes S Faderl S O'Brien FJ Giles G Garcia-Manero MA Rodriguez F Cabanillas H Kantarjian 2006 Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia Cancer 106 120 127
47. J van Asperen AH Schinkel JH Beijnen WJ Nooijen P Borst O van Tellingen 1996 Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice J Natl Cancer Inst 88 994 999
48. MS Webb TO Harasym D Masin MB Bally LD Mayer 1995 Sphingomyelin- cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models Br J Cancer 72 896 904
49. PK Working AD Dayan 1996 Pharmacological-toxicological expert report-Caelyx(TM) (Stealth(R) liposomal doxorubicin HCl)-Foreword Hum Exp Toxicol 15 751 785
50. AM Wu PD Senter 2005 Arming antibodies: prospects and challenges for immunoconjugates Nat Biotechnol 23 1137 1146
51. IV Zhigaltsev N Maurer QF Akhong R Leone E Leng J Wang SC Semple PR Cullis 2005 Liposome-encapsulated vincristine, vinblastine and vinorelbine: a comparative study of drug loading and retention J Control Release 104 103 111
52. G Zhu E Oto J Vaage Y Quinn M Newman C Engbers P Uster 1996 The effect of vincristine-polyanion complexes in STEALTH liposomes on pharmacokinetics, toxicity and anti tumor activity Cancer Chemother Pharmacol 39 138 142